Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial

St́phane Potvin, Emmanuel Stip, Olivier Lipp, Robert Élie, Adham Mancini-Marië, Marie France Demers, Marc André Roy, Roch Hugo Bouchard, Alain Gendron

Research output: Contribution to journalArticlepeer-review

66 Citations (Scopus)


Background: Preliminary evidence suggests that clozapine relieves the craving for psychoactive substances in schizophrenia patients. Quetiapine shares crucial pharmacological properties with clozapine. Promising results have been described with quetiapine therapy in patients with psychosis and substance use disorder. Methods: Based on Diagnostic and Statistical Manual of Mental Disorders - fourth edition (DSM-IV) criteria, patients were diagnosed with comorbid schizophrenia-spectrum and substance use disorders. Patients were switched to quetiapine for a 12-week open-label trial. Craving, quantities used, days of consumption, and severity of substance abuse were assessed every 3 weeks. Alcohol and Drug Use Scales were administered on baseline and endpoint. Psychiatric symptoms, depressive symptoms, extrapyramidal symptoms, and cognition were also assessed at baseline, week 6 and week 12. Results: Twenty-four schizophrenia-spectrum patients were included in the last observation carried forward (LOCF) analyses, responding to one or more of the following substance use disorders: cannabis (15 patients), alcohol (10 patients), and other psychoactive substances (nine patients). Overall, severity of substance abuse improved during the study. Less weekly days were spent on drugs of abuse. A decrease in the weekly Canadian dollars spent on psychoactive substances was also observed. Cognition, psychiatric, depressive, and extrapyramidal symptoms also significantly improved (p < 0.05). Conclusions: In this open-label, uncontrolled trial, significant improvements were noted in substance abuse, psychiatric symptoms, extrapyramidal symptoms, and cognition during quetiapine therapy. The study suffered from three main limitations: (1) the open-label design of the study; (2) the patients' poor compliance; and (3) the small sample size involved. Controlled studies on the use of quetiapine in dual diagnosis schizophrenia are warranted to confirm that the effects are drug-related.

Original languageEnglish
Pages (from-to)1277-1285
Number of pages9
JournalCurrent Medical Research and Opinion
Issue number7
Publication statusPublished - Jul 2006
Externally publishedYes


  • Atypical antipsychotics
  • Cognition
  • Extrapyramidal symptoms
  • Positive and negative symptoms
  • Quetiapine
  • Schizophrenia
  • Substance use disorders

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial'. Together they form a unique fingerprint.

Cite this